Serotonin News and Research

Latest Serotonin News and Research

Novel antidepressant appears to be safe, effective against depression in clinical trial

A small clinical trial of a novel antidepressant that stimulates neurogenesis - the production of new brain cells - shows that the compound appears to be safe and may be effective against depression.

9 Dec 2015

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study.

1 Dec 2015

Certain platelet-derived growth factors can encourage regeneration of liver tissue following surgery

A team of researchers at the MedUni Vienna has discovered that certain platelet-derived growth factors are of major significance for the liver's regeneration processes. It has been shown that platelets can encourage the regrowth of liver tissue in patients who have had parts of their liver removed surgically.

23 Nov 2015

Researchers identify genetic mutation associated with reckless drunken behavior

University of Helsinki researchers have identified a genetic mutation which renders carriers susceptible to particularly impulsive and reckless behaviour when drunk. More than one hundred thousand Finns carry this mutation.

17 Nov 2015

Athletes and non-athletes gather at TCS New York City Marathon

Well known for its culture, theater, and cuisine, New York is also one of the 25 healthiest cities in the United States. It's this fitness side that will be on show this weekend with the TCS New York City Marathon.

31 Oct 2015

Study finds no consistent evidence that antidepressants increase complications after plastic surgery

For patients undergoing plastic surgery procedures, there's no consistent evidence that taking antidepressants increases the risk of bleeding, breast cancer, or other adverse outcomes, concludes a research review in the November issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

31 Oct 2015

Pre-clinical study demonstrates positive effects of advanced prebiotic on neuro-inflammation, anxiety

Clasado Biosciences Limited, the producers and suppliers of the second generation prebiotic Bimuno(R) (B-GOS), a unique trans-galactooligosaccharide, and the Department of Psychiatry, University of Oxford, today announce the results of their latest pre-clinical study demonstrating a major role of the unique carbohydrate complex Bimuno against neuro-inflammation and anxiety.

28 Oct 2015

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

Evidence is mounting that drugs used to treat depression and Alzheimer's disease also can help patients recover from strokes. But there are conflicting findings from studies of these and other drugs given to recovering stroke patients.

22 Oct 2015

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.

19 Oct 2015

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

Sprout Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies.

19 Oct 2015

Research shows sex change hormonal treatment also changes brain chemistry

Hormonal treatments administered as part of the procedures for sex reassignment have well-known and well-documented effects on the secondary sexual characteristics of the adult body, shifting a recipient's physical appearance to that of the opposite sex.

9 Oct 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

8 Oct 2015

Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on identifying women who are candidates for treatment of menopausal symptoms and selecting the best treatment options for each individual.

8 Oct 2015

First patients screened in Axovant's phase 3 study of RVT-101

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.

6 Oct 2015

Key neurotransmitter receptor may be a potential target for individualised Autism Spectrum Disorder treatment

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered a significant—and potentially treatable—relationship between a chemical that helps transmit signals in the brain and genetic mutations present in a subset of individuals with autism spectrum disorder.

5 Oct 2015

Neuroscientists reveal the brain malady responsible for tinnitus, chronic pain

Neuroscientists at Georgetown University Medical Center and Germany's Technische Universität München say they've uncovered the brain malady responsible for tinnitus and for chronic pain — the uncomfortable, sometimes agonizing sensations that persist long after an initial injury.

24 Sep 2015

NAMS panel provides recommendations to help women manage menopause-associated vasomotor symptoms

Some three-quarters of North American women have menopausal hot flashes, but many cannot use hormones for medical reasons or choose not to. Numerous products and techniques are promoted for hot flashes, but do they work, and are they safe? To answer these questions, a North American Menopause Society panel of experts weighed the evidence and made recommendations in a position statement, "Nonhormonal management of menopause-associated vasomotor symptoms," published online today in the Society's journal, Menopause.

23 Sep 2015

People with specific genotype are more deeply affected by life experiences, reveals study

People with a certain type of gene are more deeply affected by their life experiences, a new study has revealed.

23 Sep 2015

Research examines effects of antidepressant use on health of mother and child

The use of antidepressants during pregnancy has no long term neurodevelopmental or behavioural effects on the child, however they may be associated with an increased risk of postpartum haemorrhage, suggests the findings from three studies published in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG).

16 Sep 2015

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today reported positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (alpha-7 receptor) being developed for the treatment of anxiety and depression.

16 Sep 2015

Serotonin News and Research

Latest Serotonin News and Research

Novel antidepressant appears to be safe, effective against depression in clinical trial

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Certain platelet-derived growth factors can encourage regeneration of liver tissue following surgery

Researchers identify genetic mutation associated with reckless drunken behavior

Athletes and non-athletes gather at TCS New York City Marathon

Study finds no consistent evidence that antidepressants increase complications after plastic surgery

Pre-clinical study demonstrates positive effects of advanced prebiotic on neuro-inflammation, anxiety

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

Research shows sex change hormonal treatment also changes brain chemistry

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Endocrine Society issues Clinical Practice Guideline on treatment of menopausal symptoms

First patients screened in Axovant's phase 3 study of RVT-101

Key neurotransmitter receptor may be a potential target for individualised Autism Spectrum Disorder treatment

Neuroscientists reveal the brain malady responsible for tinnitus, chronic pain

NAMS panel provides recommendations to help women manage menopause-associated vasomotor symptoms

People with specific genotype are more deeply affected by life experiences, reveals study

Research examines effects of antidepressant use on health of mother and child

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Serotonin News and Research

Latest Serotonin News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in